Cord blood stem cell therapy - Aastrom Biosciences

Drug Profile

Cord blood stem cell therapy - Aastrom Biosciences

Alternative Names: CB-I cord blood cell therapy

Latest Information Update: 17 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aastrom Biosciences
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 17 Nov 2003 Discontinued - Phase-III for Haematological malignancies in USA (unspecified route)
  • 28 Feb 2001 Phase-III clinical trials in Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top